Skip to main content
Vericel Corp logo

Vericel Corp — Investor Relations & Filings

Ticker · VCEL ISIN · US92346J1088 LEI · 54930076YM3PLTDR4B91 US Manufacturing
Open in API
Filings indexed 1,130 across all filing types
Latest filing 2011-08-15 Interim / Quarterly Rep…
Country US United States of America
Listing US VCEL

About Vericel Corp

https://vcel.com/

Vericel Corporation is a biopharmaceutical company that develops, manufactures, and commercializes advanced cell therapies for the sports medicine and severe burn care markets. The company's portfolio is centered on autologous (patient-specific) cell-based products. Key commercial products include MACI® (autologous cultured chondrocytes on porcine collagen membrane), a tissue-engineered product for the repair of symptomatic cartilage defects of the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for patients with severe burns. Additionally, Vericel holds the exclusive North American commercial rights for NexoBrid®, a biological orphan product used for the removal of eschar in adults with deep partial-thickness or full-thickness thermal burns.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2011
2011-08-15 English
FORM 4 -
Director's Dealing
2011-08-12 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 11, 2011, by Aastrom Biosciences, Inc. It reports the adoption of a shareholder rights plan and details the terms of the Shareholder Rights Agreement. The content focuses on a material agreement entered into by the company and the declaration of a dividend distribution of preferred stock purchase rights. There is no financial statement or earnings data presented, nor is it an annual or quarterly report. The document is not a call transcript, proxy statement, or remuneration report. It is a current report disclosing a material event related to capital structure and shareholder rights. This fits best under Capital/Financing Update (CAP) as it concerns a shareholder rights plan and related capital structure changes. The document length is over 10,000 characters and contains substantive detail about the agreement, not just an announcement or reference to a report, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2011-08-12 English
FORM 4 -
Director's Dealing
2011-08-12 English
REGISTRATION/LISTING OF SECURITIES ON A NATIONAL SECURITIES EXCHANGE
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It describes the registration of Preferred Stock Purchase Rights and includes detailed terms of a Shareholder Rights Agreement. The document is a regulatory filing related to securities registration and does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. It is also not an announcement of a report but the actual registration statement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2011-08-12 English
FORM 4 -
Director's Dealing
2011-08-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.